Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio
Producing medicines for the United States, the plant features innovative technologies and advancements in sustainability
New $20 Million Grant Will Help Johns Hopkins Develop Technologies for Healthy Aging
Multicenter 'collaboratory' will focus on the use of artificial intelligence to improve long-term health, independence for older people
SciSparc Ltd: This Innovative Biotech May Have a 3.5x Upside
Meet SciSparc Ltd., the biotech disruptor with potential pipeline revenues of about $490,926,545
OcyonBio Appoints Robert Salcedo as Chief Executive Officer
OcyonBio CDMO welcomes cell and gene therapy expert Robert Salcedo who brings over 20 years of expertise in the areas of CMC, operations, and supply chain management and has served in multi-billion-dollar companies operating in biotech, vaccines, and pharmaceutical markets.
Innocan Pharma’s Breakthrough: Diabetic Foot Relief Treatment Demonstrates Remarkable Efficacy
Unlocking Market Potential: Innocan Pharma's Breakthrough Cream Shows Promise in Diabetic Foot Care
Nuvectis Pharma Reports Q1 Results, Expects Several Clinical Updates in H2 2024
Nuvectis Chairman & CEO Ron Bentsur: “2024 is shaping up to be a potentially transformational year for Nuvectis with several clinical data updates expected in the second half of the year.”
There Are Early Signals Ahead of Tafamidis Trial As Analysts See Potential Upside for Pfizer (PFE) and BridgeBio Pharma (BIO)
PharmaWire has reported on the tafamidis patent trial ahead of its scheduled court date on 27 April. Analysts have pointed to early signs that may be shaping expectations for Pfizer (NYSE: PFE), BridgeBio (NASDAQ: BBIO) and the broader ATTR-CM market.
EyePoint Pharmaceuticals Agrees to Pay $4.6 Million to Settle False Claims Act Allegations
Massachusetts based drugmaker resolves claims it used kickbacks and free samples to boost sales of an eye medication used after cataract surgery, highlighting ongoing scrutiny of pharmaceutical marketing practices.